MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-06-30.

Income Overview

Net Income
-$25,496K
EPS
-$0.49
Unit: Thousand (K) dollars

Income Statement
2025-06-30
Research and development
21,491
General and administrative
7,093
Total operating expenses
28,584
Loss from operations
-28,584
Other expense
-2
Interest income
3,251
Income tax expense
0
Change in fair value of contingent value right liability
0
Total other income (expense), net
3,249
Net loss
-25,335
Net unrealized losses on marketable securities
-161
Comprehensive loss
-25,496
Basic EPS
-0.49
Diluted EPS
-0.49
Basic Average Shares
52,105,052
Diluted Average Shares
52,105,052
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$25,496K Interest income$3,251K Net loss-$25,335K Net unrealizedlosses on marketable...-$161K Total other income(expense), net$3,249K Other expense-$2K Loss from operations-$28,584K Total operatingexpenses$28,584K Research and development$21,491K General andadministrative$7,093K

Enliven Therapeutics, Inc. (IMRA)

Enliven Therapeutics, Inc. (IMRA)